What does ASSOP Monitor

• The AMR rates and resistant phenotypes of community-onset and hospital-onset Staphylococcus aureus bloodstream infections by jurisdiction.

• The percentage of community Staphylococcus aureus bloodstreamed infections caused by Panton Valentine leucocidin (PVL) -positive and -negative methicillin-resistant Staphylococcus aureus (MRSA).

• The important community-associated (CA) MRSA and hospital-associated (HA) MRSA clones in Australia by jurisdiction.

• The emergence and spread of PVL-positive and -negative CA-MRSA clones in Australia by jurisdiction.

• The transmission of the PVL genes into naïve clones.

• Infection types associated with Staphylococcus aureus bloodstream infections.

• Outcomes (30-day all-cause mortality, length of stay post-episode) by community- versus hospital-onset, and for methicillin-susceptible Staphylococcus aureus, CA-MRSA and HA-MRSA.

• Using data from previous ASSOP surveys providing analysis and commentary on the importance of trends by jurisdiction for clinical practice and the response to AMR.

Why does it Matter

MRSA is one of Australia’s most important AMR threats and is part of the high priority tier in the WHO Bacterial Priority Pathogens List.

ASSOP data:

• Guides empirical therapy for Staphylococcus aureus bacteraemia

• Assists hospital infection control policies

• Provides national AMR data to AURA and MRSA prevalence rates to the World Health Organisation’s Global Antimicrobial Resistance and Use Surveillance System (GLASS)